-
1
-
-
0036638328
-
Epidermal growth factor receptor as a therapeutic target in head and neck cancer
-
Bonner J.A., De Los Santos J., Waksal H.W., et al. Epidermal growth factor receptor as a therapeutic target in head and neck cancer. Semin Radiat Oncol. 12:(3(Suppl. 2)):2002;11-20.
-
(2002)
Semin Radiat Oncol
, vol.12
, Issue.3 SUPPL. 2
, pp. 11-20
-
-
Bonner, J.A.1
De Los Santos, J.2
Waksal, H.W.3
-
2
-
-
0033966576
-
In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
-
Milas L., Mason K., Hunter N., et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 6:2000;701-708.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 701-708
-
-
Milas, L.1
Mason, K.2
Hunter, N.3
-
3
-
-
0032478998
-
Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival
-
Grandis J.R., Melhem M.F., Gooding W.E., et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 90:1998;824-832.
-
(1998)
J Natl Cancer Inst
, vol.90
, pp. 824-832
-
-
Grandis, J.R.1
Melhem, M.F.2
Gooding, W.E.3
-
4
-
-
17344382185
-
Combined modality therapy of A431 human epidemloid cancer using anti-EGFr antibody C225 and radiation
-
Saleh M.N., Raisch K.P., Stackhouse M.A., et al. Combined modality therapy of A431 human epidemloid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm. 14:1999;451-463.
-
(1999)
Cancer Biother Radiopharm
, vol.14
, pp. 451-463
-
-
Saleh, M.N.1
Raisch, K.P.2
Stackhouse, M.A.3
-
5
-
-
0033561522
-
Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
-
Huang S.M., Bock J.M., Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59:1999;1935-1940.
-
(1999)
Cancer Res
, vol.59
, pp. 1935-1940
-
-
Huang, S.M.1
Bock, J.M.2
Harari, P.M.3
-
6
-
-
0037010086
-
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer
-
Herbst R.S., Hong W.K. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Semin Oncol. 29:(5(Suppl. 14)):2002;18-30.
-
(2002)
Semin Oncol
, vol.29
, Issue.5 SUPPL. 14
, pp. 18-30
-
-
Herbst, R.S.1
Hong, W.K.2
-
7
-
-
1242311470
-
EGFR-targeted agents potentiate the antitumour activity of chemotherapy and radiotherapy
-
Ciardiello F. EGFR-targeted agents potentiate the antitumour activity of chemotherapy and radiotherapy. Signal. 2:2001;4-11.
-
(2001)
Signal
, vol.2
, pp. 4-11
-
-
Ciardiello, F.1
-
8
-
-
1242266425
-
EGFR-targeted cancer therapies: Is there a need to reconsider clinical trial design?
-
Rowinsky EK. EGFR-targeted cancer therapies: Is there a need to reconsider clinical trial design? Signal 2001;2:1, 4-11.
-
(2001)
Signal
, vol.2
, pp. 1
-
-
Rowinsky, E.K.1
-
9
-
-
0034114769
-
Blockade of receptors for growth factors: An anticancer therapy - The Fourth Annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture
-
Mendelson J. Blockade of receptors for growth factors An anticancer therapy - The Fourth Annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture . Clin Cancer Res. 6:2000;747-753.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 747-753
-
-
Mendelson, J.1
-
10
-
-
1242289115
-
Anti-EGFr-mediated radiosensitization as a result of augmented EGFr expression
-
in press
-
Bonner JA, Buchsbaum DJ, Russo SM, et al. Anti-EGFr-mediated radiosensitization as a result of augmented EGFr expression. Int J Radiat Oncol Biol Phys 2004; in press.
-
(2004)
Int J Radiat Oncol Biol Phys
-
-
Bonner, J.A.1
Buchsbaum, D.J.2
Russo, S.M.3
-
12
-
-
1242333984
-
Radiolabeled ligand binding to cells induced to express the epidermal growth factor receptor using a recombinant adenoviral vector
-
Rogers B., Curiel D., Khazaeli M., et al. Radiolabeled ligand binding to cells induced to express the epidermal growth factor receptor using a recombinant adenoviral vector. J Nucl Med. 18:1997;18.
-
(1997)
J Nucl Med
, vol.18
, pp. 18
-
-
Rogers, B.1
Curiel, D.2
Khazaeli, M.3
-
13
-
-
17444427673
-
Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer
-
Miller C.R., Buchsbaum D.J., Reynolds P.N., et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer . Cancer Res. 58:1998;5738-5748.
-
(1998)
Cancer Res
, vol.58
, pp. 5738-5748
-
-
Miller, C.R.1
Buchsbaum, D.J.2
Reynolds, P.N.3
-
14
-
-
0032448768
-
Targeting adenoviral infection with basic fibroblast growth factor enhances gene delivery to vascular endothelial and smooth muscle cells
-
Reynolds P.N., Miller C.R., Goldman C.K., et al. Targeting adenoviral infection with basic fibroblast growth factor enhances gene delivery to vascular endothelial and smooth muscle cells. Tumor Targeting. 3:1998;156-168.
-
(1998)
Tumor Targeting
, vol.3
, pp. 156-168
-
-
Reynolds, P.N.1
Miller, C.R.2
Goldman, C.K.3
-
15
-
-
0032456772
-
Genetic induction of antigens and receptors as targets for cancer radiotherapy
-
Rogers B.E., Garver R.I. Jr., Grizzle W.E., et al. Genetic induction of antigens and receptors as targets for cancer radiotherapy. Tumor Targeting. 3:1998;122-137.
-
(1998)
Tumor Targeting
, vol.3
, pp. 122-137
-
-
Rogers, B.E.1
Garver Jr., R.I.2
Grizzle, W.E.3
-
16
-
-
0037111274
-
Treatment of pancreatic cancer xenografts with erbitu (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation
-
Buchsbaum D.J., Bonner J.A., Grizzle W.E., et al. Treatment of pancreatic cancer xenografts with erbitu (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys. 54:2002;1180-1193.
-
(2002)
Int J Radiat Oncol Biol Phys
, vol.54
, pp. 1180-1193
-
-
Buchsbaum, D.J.1
Bonner, J.A.2
Grizzle, W.E.3
-
17
-
-
0033010379
-
Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinoma
-
Myers R.B., Oelschlager D., Manne U., et al. Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinoma. Int J Cancer. 82:1999;424-429.
-
(1999)
Int J Cancer
, vol.82
, pp. 424-429
-
-
Myers, R.B.1
Oelschlager, D.2
Manne, U.3
-
18
-
-
0001782009
-
Immunohistochemical evaluation of biomarkers in prostatic and colorectal neoplasia
-
M. Hanausek, & Z. Walasezek. Totowa, NJ: Humana Press, Inc
-
Grizzle W.E., Myers R.B., Manne U., et al. Immunohistochemical evaluation of biomarkers in prostatic and colorectal neoplasia. Hanausek M., Walasezek Z. John Walker's methods in molecular medicine. Tumor marker protocols. 1998;143-160 Humana Press, Inc, Totowa, NJ.
-
(1998)
John Walker's Methods in Molecular Medicine. Tumor Marker Protocols
, pp. 143-160
-
-
Grizzle, W.E.1
Myers, R.B.2
Manne, U.3
-
19
-
-
0002634867
-
Factors affecting immunohistochemical evaluation of biomarker expression in neoplasia
-
M. Hanausek, & Z. Walaszek. Totowa, NJ: Humana Press, Inc
-
Grizzle W.E., Myers R.B., Manne U., et al. Factors affecting immunohistochemical evaluation of biomarker expression in neoplasia. Hanausek M., Walaszek Z. John Walker's methods in molecular medicine. Tumor marker protocols. 1998;161-179 Humana Press, Inc, Totowa, NJ.
-
(1998)
John Walker's Methods in Molecular Medicine. Tumor Marker Protocols
, pp. 161-179
-
-
Grizzle, W.E.1
Myers, R.B.2
Manne, U.3
-
20
-
-
0030873487
-
2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer
-
2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer. J Nucl Med. 38:1997;1221-1229.
-
(1997)
J Nucl Med
, vol.38
, pp. 1221-1229
-
-
Rogers, B.E.1
Rosenfeld, M.E.2
Khazaeli, M.B.3
-
21
-
-
0027255975
-
Purification of radiolabeled monoclonal antibodies to angiotensin-converting enzyme significantly improves specificity and efficacy of its targeting into the lung
-
Hiemisch H., Gavrilyuk V., Atochina E., et al. Purification of radiolabeled monoclonal antibodies to angiotensin-converting enzyme significantly improves specificity and efficacy of its targeting into the lung. Nucl Med Biol. 20:1993;435-441.
-
(1993)
Nucl Med Biol
, vol.20
, pp. 435-441
-
-
Hiemisch, H.1
Gavrilyuk, V.2
Atochina, E.3
-
22
-
-
0034329308
-
Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers
-
Bonner JA, Raisch KP, Trummell HQ, et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 2000;18:21(Suppl. 1):47s-53s.
-
(2000)
J Clin Oncol
, vol.18
, Issue.21 SUPPL. 1
-
-
Bonner, J.A.1
Kp, R.2
Trummell, H.Q.3
-
23
-
-
0004216962
-
-
Boston, MA: Little Brown. p. 131-136
-
Colton T. Statistics in medicine. 1974;Little Brown, Boston, MA. p. 131-136.
-
(1974)
Statistics in medicine
-
-
Colton, T.1
-
24
-
-
0037211253
-
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): Simple drugs with a complex mechanism of action
-
Nicola N., Maiello M.R., De Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) Simple drugs with a complex mechanism of action . J Cell Physiol. 194:2002;13-19.
-
(2002)
J Cell Physiol
, vol.194
, pp. 13-19
-
-
Nicola, N.1
Maiello, M.R.2
De Luca, A.3
-
25
-
-
0035892346
-
ZD 1839 (IRESSA): A novel epidermal growth factor receptor (EGRR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without ERBB2 overexpression
-
Anderson N.G., Ahmad T., Chan K., et al. ZD 1839 (IRESSA) A novel epidermal growth factor receptor (EGRR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without ERBB2 overexpression . Int J Cancer. 94:2001;774-782.
-
(2001)
Int J Cancer
, vol.94
, pp. 774-782
-
-
Anderson, N.G.1
Ahmad, T.2
Chan, K.3
-
26
-
-
0036690404
-
Effects of the epidermal growth factor receptor inhibitor OSI-774, tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma
-
Ng S.W., Tsao M.S., Nicklee T., et al. Effects of the epidermal growth factor receptor inhibitor OSI-774, tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther. 1:2002;777-783.
-
(2002)
Mol Cancer Ther
, vol.1
, pp. 777-783
-
-
Ng, S.W.1
Tsao, M.S.2
Nicklee, T.3
-
27
-
-
0034722889
-
The EGF receptor family as targets for cancer therapy
-
Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 19:2000;6550-6565.
-
(2000)
Oncogene
, vol.19
, pp. 6550-6565
-
-
Mendelsohn, J.1
Baselga, J.2
-
28
-
-
0028208423
-
Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer of head and neck cancer treated with monoclonal antibody RG 83852
-
Perez-Soler R., Donato N.J., Shin D.M., et al. Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer of head and neck cancer treated with monoclonal antibody RG 83852. J Clin Oncol. 12:1994;730-739.
-
(1994)
J Clin Oncol
, vol.12
, pp. 730-739
-
-
Perez-Soler, R.1
Donato, N.J.2
Shin, D.M.3
-
29
-
-
8944263458
-
Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer
-
Modjtahedi H., Hickish T., Nicholson M., et al. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer. 73:1996;228-235.
-
(1996)
Br J Cancer
, vol.73
, pp. 228-235
-
-
Modjtahedi, H.1
Hickish, T.2
Nicholson, M.3
-
30
-
-
0035117355
-
Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
-
Yang X.D., Jia X.C., Corvalan J.R., et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol. 38:2001;17-23.
-
(2001)
Crit Rev Oncol
, vol.38
, pp. 17-23
-
-
Yang, X.D.1
Jia, X.C.2
Corvalan, J.R.3
-
31
-
-
0000583326
-
Monoclonal antibody (MoAb) IMC-C225 and anti-epidermal growth factor receptor (EGFr) positive tumors refractory to or in relapse from previous therapeutic regimens
-
Rubin MS, Shin DM, Pasmantier M, et al. Monoclonal antibody (MoAb) IMC-C225 and anti-epidermal growth factor receptor (EGFr) positive tumors refractory to or in relapse from previous therapeutic regimens. Proc Annu Meet Am Soc Clin Oncol 2000;19:474a.
-
(2000)
Proc Annu Meet Am Soc Clin Oncol
, vol.19
-
-
Rubin, M.S.1
Shin, D.M.2
Pasmantier, M.3
-
32
-
-
0035398021
-
Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer
-
Robert F., Ezekiel M.P., Spencer S.A., et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 13:2001;3234-3243.
-
(2001)
J Clin Oncol
, vol.13
, pp. 3234-3243
-
-
Robert, F.1
Ezekiel, M.P.2
Spencer, S.A.3
-
33
-
-
0036304685
-
Local recurrence in head and neck cancer: Relationship to radiation resistance and signal transduction
-
Gupta A.K., McKenna W.G., Weber C.N., et al. Local recurrence in head and neck cancer Relationship to radiation resistance and signal transduction . Clin Cancer Res. 8:2002;885-892.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 885-892
-
-
Gupta, A.K.1
McKenna, W.G.2
Weber, C.N.3
-
34
-
-
0036681993
-
The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in RAS-dependent manner
-
Chakravarti A., Chakladar A., Delaney M.A., et al. the epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in RAS-dependent manner. Cancer Res. 62:2002;4307-4315.
-
(2002)
Cancer Res
, vol.62
, pp. 4307-4315
-
-
Chakravarti, A.1
Chakladar, A.2
Delaney, M.A.3
-
36
-
-
0033584391
-
Dominant negative EGFr-CD533 anti-inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells
-
Reardon D.B., Contessa J.N., Dent R.P., et al. Dominant negative EGFr-CD533 anti-inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. Oncogene. 18:(Suppl. 33):1999;4756-4766.
-
(1999)
Oncogene
, vol.18
, Issue.SUPPL. 33
, pp. 4756-4766
-
-
Reardon, D.B.1
Contessa, J.N.2
Dent, R.P.3
-
37
-
-
0030693984
-
Cip1 in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors
-
Cip1 in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin Cancer Res. 3:1997;1943-1948.
-
(1997)
Clin Cancer Res
, vol.3
, pp. 1943-1948
-
-
Fan, Z.1
Shang, B.Y.2
Lu, Y.3
-
38
-
-
0036328973
-
Epidermal growth factor receptor dependence of radiation-induced transcription factor activation in human breast carcinoma cells
-
Amorino G.P., Hamilton V.M., Valerie K., et al. Epidermal growth factor receptor dependence of radiation-induced transcription factor activation in human breast carcinoma cells. Mol Biol Cell. 13:2002;2233-2244.
-
(2002)
Mol Biol Cell
, vol.13
, pp. 2233-2244
-
-
Amorino, G.P.1
Hamilton, V.M.2
Valerie, K.3
-
39
-
-
0013689209
-
Requirement of STAT3 but not STAT1 activation for epidermal growth factor receptor-mediated cell growth in vitro
-
Grandis J.R., Drenning S.D., Chakraborty A., et al. Requirement of STAT3 but not STAT1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest. 102:1998;1385-1392.
-
(1998)
J Clin Invest
, vol.102
, pp. 1385-1392
-
-
Grandis, J.R.1
Drenning, S.D.2
Chakraborty, A.3
-
40
-
-
0033925797
-
Ectodomain of coxackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells
-
Dmitriev I., Kashentseva E., Rogers B.E., et al. Ectodomain of coxackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol. 74:2000;6875-6884.
-
(2000)
J Virol
, vol.74
, pp. 6875-6884
-
-
Dmitriev, I.1
Kashentseva, E.2
Rogers, B.E.3
-
41
-
-
0034895056
-
Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids
-
Grill J., Van Beusechem V.W., Van Der Valk P., et al. combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin Cancer Res. 7:2001;641-650.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 641-650
-
-
Grill, J.1
Van Beusechem, V.W.2
Van Der Valk, P.3
-
42
-
-
0033946856
-
Targeting of adenoviral vectors through a bispecific single-chain antibody
-
Haisma H.J., Grill J., Curiel D.T., et al. Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer Gene Ther. 7:2000;901-904.
-
(2000)
Cancer Gene Ther
, vol.7
, pp. 901-904
-
-
Haisma, H.J.1
Grill, J.2
Curiel, D.T.3
-
43
-
-
0030817590
-
Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo
-
Pederson L.C., Buchsbaum D.J., Vickers S.M., et al. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Res. 57:1997;4325-4332.
-
(1997)
Cancer Res
, vol.57
, pp. 4325-4332
-
-
Pederson, L.C.1
Buchsbaum, D.J.2
Vickers, S.M.3
-
44
-
-
0034086627
-
Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models
-
Stackhouse M.A., Pederson L.C., Grizzle W.E., et al. Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models. Gene Ther. 7:2000;1019-1026.
-
(2000)
Gene Ther
, vol.7
, pp. 1019-1026
-
-
Stackhouse, M.A.1
Pederson, L.C.2
Grizzle, W.E.3
|